Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials

Published:2019-04-01 Issue:4 Volume:5 Page:457
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Roydhouse Jessica K.¹,Fiero Mallorie H.²,Kluetz Paul G.³

Affiliation:

1. Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland

2. Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland

3. Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/4/457/17459177/jamaoncology_roydhouse_2019_vp_180029.pdf

Reference7 articles.

1. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study.;Wood;BMJ,2008

2. Trustworthiness of patient-reported outcomes in unblinded cancer clinical trials.;Atkinson;JAMA Oncol,2017

3. Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials.;Basch;JAMA Oncol,2017

4. Disappointment and drop-out rate after being allocated to control group in a smoking cessation trial.;Lindström;Contemp Clin Trials,2010

5. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.;Sridhara;Clin Cancer Res,2013

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer;The Lancet Regional Health - Western Pacific;2024-07

2. Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial;American Journal of Hematology;2024-06-17

3. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS);HemaSphere;2024-05

4. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial;The Lancet Oncology;2024-05

5. Critical Comments by Food and Drug Administration Reviewers on Patient-Reported Outcomes in Food and Drug Administration Regulatory Submissions (2018-2021);Value in Health;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3